Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2833 - Real life registry data of primary localisation of a well-defined colon cancer population of Western Austria (Salzburg, Tyrol and Vorarlberg), Eastern Switzerland (St.Gallen and Graubünden) and Liechtenstein.

Date

09 Sep 2017

Session

Poster display session

Topics

Colon and Rectal Cancer

Presenters

Bernd Hartmann

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

B.L. Hartmann1, W. Oberaigner2, H. Frick3, L. Weiss4, T. Winder1, K. Philipp-Abbrederis5, C. Herrmann3, M.Q. Huynh6, G. Spizzo5, C.M. Lang7, A. Seeber5, J. Schneider8, E. Wöll9, P. Mosler10, R. Greil4, M. Rössle11, H. Rumpold1, G. Gastl5, R. von Moos12, A.H. Lang13

Author affiliations

  • 1 Innere Medizin Ii, LKH Feldkirch, 6800 - Feldkirch/AT
  • 2 Iet, Tirol Kliniken, 6020 - Innsbruck/AT
  • 3 Krebsregister, Kantonsspital St.Gallen, 9000 - St. Gallen/CH
  • 4 Internal Medicine Iv, Landeskrankenhaus Salzburg - Universitätsklinikum der PMU,, 5020 - Salzburg/AT
  • 5 Haematology And Oncology, Innsbruck Medical University, 6020 - Innsbruck/AT
  • 6 Innere Medizin, LKH Bregenz, 6900 - Bregenz/AT
  • 7 Chirurgie, LKH Bregenz, 6900 - Bregenz/AT
  • 8 Pathologie, LKH Feldkirch, 6800 - Feldkirch/AT
  • 9 Innere Medizin, Krankenhaus St. Vinzenz-Zams Spital Tirol Oberland, 6511 - Zams/AT
  • 10 Gastroenterology, Kantonsspital Graubünden, Chur/CH
  • 11 Pathology, Kantonsspital Graubünden, 8000 - Chur/CH
  • 12 Oncology, Kantonsspital Graubünden, 8000 - Chur/CH
  • 13 Krebsregister Vorarlberg, AKS, 6900 - Bregenz/AT
More

Resources

Abstract 2833

Background

Primary tumors arising from different regions of the colon are biologically distinct; thus location is associated with different features such as microbiota and molecular alterations. Recently, retrospective analysis of phase III trials have shown better prognosis and a significant benefit of anti-EGFR antibodies in left sided RAS wild-type metastatic colon cancer patients. Epidemiological analysis of colon cancer patients from the neighbouring Cancer Registries of Salzburg, Tyrol and Vorarlberg, St. Gallen, Graubünden, and Liechtenstein was to support different prognostic value of left-and right-sided colon cancer.

Methods

7626 patients with pathologically confirmed colon cancer diagnosed between 2005 and 2015 were identified from the database of the population-based cancer registries of Western Austria, Eastern Switzerland and Liechtenstein. Patients were categorized in two groups: Right-sided colon cancer (RCC) including tumors of the colon transversum and left-sided colon cancer (LCC). Analysis was conducted separately for UICC stages III and IV. Survival curves were estimated applying the Kaplan-Meier method; for comparison of RCC and LCC cohorts the Logrank test was applied. Tumor stage and localisation are shown in the following table.Table:

599P

Staging UICCRCCLCCTotal
I626 (16.7%)918 (23.6%)1544 (20.2%)
II1091 (29.2%)979 (25.2%)2070 (27.1%)
III995 (26.6%)1016 (26.1%)2011 (26.4%)
IV863 (23.1%)807 (20.8%)1670 (21.9%)
X/nos164 (4.4%)167 (4.3%)331 (4.3%)
Total3739 (100.0%)3887 (100.0%)7626 (100.0%)

Results

Tumor location per se in stage III and IV colon cancer in the current retrospectively, epidemiological study, revealed a significantly better overall survival for LCC than for RCC in stage III and IV in a univariate analysis. After stratification by age, hazard ratio was 0.91 (95% Confidence interval 0.78-1.07) in stage III and 0.75 (95% confidence interval 0.66-0.84) in stage IV, thereby confirming recent, retrospective data from large phase III clinical trials (FIRE-3, CHRYSTAL; PEAK and PRIME).

Conclusions

Real life registry data of a well- defined colon cancer population confirm retrospective clinical trial data that LCC in stage III and IV carry a more favourable outcome than RCC, even in the era of modern chemo-immunotherapy.

Clinical trial identification

Legal entity responsible for the study

Alois H. Lang

Funding

Krebsregister Vorarlberg

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.